ArticleFrontiers in pharmacology2026
Eucommia ulmoides extract and soy isoflavones attenuate postmenopausal osteoporosis by modulating bone-specific transcription factors and inflammatory signaling pathways.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postmenopausal osteoporosis (PMO) is driven by estrogen deficiency, enhanced osteoclastic activity, impaired osteoblast function, and persistent inflammatory signaling. Eucommia ulmoides extract (EUE) and soy isoflavones (Isf) are known to possess phytoestrogenic and anti-inflammatory properties, but their combined molecular effects on PMO remain unclear. Methods: An ovariectomy-induced PMO rat model was used to assess the therapeutic efficacy of EUE, Isf, and their combination. Bone strength and mineral content were evaluated together with serum indicators of bone turnover, including type I procollagen N-terminal propeptide, alkaline phosphatase, C-terminal telopeptide of type I collagen, and tartrate-resistant acid phosphatase. Serum calcium, phosphorus, superoxide dismutase, and malondialdehyde levels were also measured. Trabecular microarchitecture was assessed histologically. Results: The combined EUE and Isf treatment significantly improved biomechanical performance of the femur and restored bone mineral content in ovariectomized rats. Levels of bone formation markers were elevated, whereas indices of bone resorption were reduced. Serum calcium-phosphorus homeostasis and oxidative stress were markedly corrected, accompanied by substantial improvement in trabecular structure. Conclusion: EUE combined with soy isoflavones effectively attenuates postmenopausal osteoporosis by enhancing osteoblast function, suppressing osteoclastogenesis, and rebalancing bone-related transcriptional and inflammatory pathways. This botanical combination represents a promising therapeutic strategy for the management of PMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.